South Korea · Delayed Price · Currency is KRW ABL Bio Statistics
Total Valuation
ABL Bio has a market cap or net worth of KRW 5.10 trillion. The enterprise value is 4.97 trillion.
| Market Cap | 5.10T |
| Enterprise Value | 4.97T |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABL Bio has 55.99 million shares outstanding. The number of shares has increased by 10.68% in one year.
| Current Share Class | 55.99M |
| Shares Outstanding | 55.99M |
| Shares Change (YoY) | +10.68% |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 25.75% |
| Owned by Institutions (%) | 10.82% |
| Float | 41.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 56.47 |
| PB Ratio | 27.82 |
| P/TBV Ratio | 28.72 |
| P/FCF Ratio | 763.67 |
| P/OCF Ratio | 255.60 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 55.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 744.12 |
Financial Position
The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.70 |
| Quick Ratio | 1.67 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | 8.31 |
| Interest Coverage | -20.33 |
Financial Efficiency
Return on equity (ROE) is -14.95% and return on invested capital (ROIC) is -8.40%.
| Return on Equity (ROE) | -14.95% |
| Return on Assets (ROA) | -7.02% |
| Return on Invested Capital (ROIC) | -8.40% |
| Return on Capital Employed (ROCE) | -15.52% |
| Weighted Average Cost of Capital (WACC) | 5.35% |
| Revenue Per Employee | 885.50M |
| Profits Per Employee | -236.63M |
| Employee Count | 102 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.30% in the last 52 weeks. The beta is 0.21, so ABL Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +14.30% |
| 50-Day Moving Average | 133,098.00 |
| 200-Day Moving Average | 148,181.50 |
| Relative Strength Index (RSI) | 29.94 |
| Average Volume (20 Days) | 471,632 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABL Bio had revenue of KRW 90.32 billion and -24.14 billion in losses. Loss per share was -452.97.
| Revenue | 90.32B |
| Gross Profit | 90.21B |
| Operating Income | -28.58B |
| Pretax Income | -24.39B |
| Net Income | -24.14B |
| EBITDA | -24.72B |
| EBIT | -28.58B |
| Loss Per Share | -452.97 |
Balance Sheet
The company has 188.79 billion in cash and 55.49 billion in debt, with a net cash position of 133.29 billion or 2,380.77 per share.
| Cash & Cash Equivalents | 188.79B |
| Total Debt | 55.49B |
| Net Cash | 133.29B |
| Net Cash Per Share | 2,380.77 |
| Equity (Book Value) | 183.34B |
| Book Value Per Share | 3,226.22 |
| Working Capital | 79.54B |
Cash Flow
In the last 12 months, operating cash flow was 19.95 billion and capital expenditures -13.28 billion, giving a free cash flow of 6.68 billion.
| Operating Cash Flow | 19.95B |
| Capital Expenditures | -13.28B |
| Depreciation & Amortization | 3.86B |
| Net Borrowing | 11.61B |
| Free Cash Flow | 6.68B |
| FCF Per Share | 119.29 |
Margins
Gross margin is 99.87%, with operating and profit margins of -31.64% and -26.72%.
| Gross Margin | 99.87% |
| Operating Margin | -31.64% |
| Pretax Margin | -27.00% |
| Profit Margin | -26.72% |
| EBITDA Margin | -27.37% |
| EBIT Margin | -31.64% |
| FCF Margin | 7.39% |
Dividends & Yields
ABL Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.68% |
| Shareholder Yield | -10.68% |
| Earnings Yield | -0.47% |
| FCF Yield | 0.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for ABL Bio is 223,200.00, which is 145.01% higher than the current price. The consensus rating is "Buy".
| Price Target | 223,200.00 |
| Price Target Difference | 145.01% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 2.72% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABL Bio has an Altman Z-Score of 32.31 and a Piotroski F-Score of 4.
| Altman Z-Score | 32.31 |
| Piotroski F-Score | 4 |